DOJ and FTC Antitrust Scrutiny Is Quietly Rewriting Strategic Acquisition Agreements
For many buyers, the biggest merger risk used to be price.
Today, it is time.
Across strategic acquisitions, the Department of Justice and the Federal Trade Commission are pushing transactions into deeper review cycles, longer second-request timelines, and far more aggressive scrutiny around how deals may reshape market structure, data control, or channel access. FY 2024 data showed 59 Second Requests, a 59% increase over the prior year, confirming that extended investigations are no longer rare events in significant transactions.
What makes this especially important is that the effect is no longer confined to mega-deals.
Mid-market transactions, private equity platform acquisitions, tuck-ins, data-rich SaaS deals, healthcare consolidations, and vertical rollups are increasingly being diligenced through an antitrust lens long before the Hart-Scott-Rodino threshold is even the headline issue. Regulators have made clear that concentration concerns can arise around exclusivity rights, data aggregation, platform control, and channel foreclosure even when the parties initially view the transaction as a straightforward private deal.
That shift is quietly rewriting how acquisition agreements themselves need to be negotiated.
The old mid-market assumption was that regulatory approval provisions were largely boilerplate. The parties would include a standard efforts covenant, insert a conventional outside date, and move toward closing with limited concern that antitrust review would materially affect deal economics.
That assumption is becoming dangerous.
The first place this shows up is in the letter of intent and exclusivity phase.
A buyer pursuing a strategic acquisition may lock up exclusivity based on synergy assumptions tied to platform consolidation, customer overlap, pricing leverage, or channel integration. But regulators are increasingly interested in how those very synergies may reduce market alternatives. MFN clauses, exclusivity arrangements, data concentration, non-competes, and channel foreclosure mechanics that once looked commercially efficient can now become part of the competition narrative.
That means antitrust diligence now begins before definitive documents.
The deeper legal consequence is appearing in stock purchase agreements and merger agreements.
Outside dates are getting longer because buyers can no longer safely assume a fast first-pass review. Even where a transaction is likely to clear, the process of responding to a second request, preserving mobile data, collecting business documents, and negotiating remedies can materially alter the original closing calendar. Reuters’ merger-review reporting continues to show that substantial-compliance exercises alone can stretch for 60 to 90 days or more.
That time pressure directly changes risk allocation.
Sellers increasingly want stronger reverse termination fees where a buyer’s regulatory risk profile is higher or where the buyer is consolidating a platform in a concentrated space. From the seller’s perspective, the opportunity cost of a failed deal is no longer theoretical. A six-month regulatory delay can disrupt management focus, customer confidence, employee retention, and parallel buyer interest.
As a result, reverse termination economics are becoming a much more important pricing variable.
The same is true for antitrust cooperation covenants.
Historically, buyers often wanted broad control over the regulatory process. Today, sellers are negotiating far more precision around what “reasonable best efforts” means, whether the buyer must offer remedies, how much divestiture pain must be accepted, and whether the buyer is required to litigate if the agency challenges the transaction.
This matters because a buyer may be willing to pursue the deal only if it can preserve a key exclusivity arrangement, a data asset, or a platform integration pathway. If the cooperation covenant is vague, the parties may discover too late that they had fundamentally different assumptions about how hard the buyer was obligated to fight for clearance.
Interim operating covenants are also under more pressure than many mid-market parties realize.
A longer regulatory review period means the target may be sitting in a quasi-frozen state for months. During that time, the seller still needs to operate competitively, renew customer agreements, respond to employee departures, adjust pricing, and preserve channel relationships. If interim covenants are drafted too tightly, the business can lose momentum while waiting for regulatory clearance. If drafted too loosely, the buyer may inherit a materially changed asset.
That tension is now a major drafting issue.
The broader business takeaway is that antitrust risk is no longer simply a filing issue.
It is now a core transaction-structuring issue that changes timing, leverage, economics, and even whether exclusivity should be granted at the LOI stage.
The companies navigating this well are not waiting until HSR counsel is brought in. They are aligning exclusivity terms, diligence scopes, outside dates, reverse termination fees, cooperation covenants, and interim operating controls with the realistic possibility of deeper merger scrutiny—even in private deals.
For founders, private equity sponsors, strategic buyers, and mid-market companies pursuing acquisitions, this is the right time to review whether your LOIs, purchase agreements, and deal timelines actually reflect the modern antitrust review environment. A focused legal review often reveals where exclusivity rights, data concentration assumptions, outside dates, and regulatory covenants break down before a second request or agency concern turns a strategic acquisition into an avoidable broken-deal problem. If your company is actively buying, selling, or rolling up businesses in a concentrated market, this is the right moment to schedule an acquisition-structure and antitrust risk review before regulatory timing silently changes deal value.